Browse the evidence

Tirzepatide can cause direct drug-induced liver injury (hepatitis) independent of gallbladder disease, characterized by elevated liver enzymes and bilirubin that normalize upon discontinuation.

If you are taking Tirzepatide and experience symptoms like jaundice, dark urine, or right-sided abdominal pain, seek medical attention immediately. Your doctor should check liver enzymes. If levels are elevated, stopping the drug typically leads to full recovery within a month, but this requires prompt medical intervention and monitoring.

Tirzepatide therapy can cause euglycaemic ketoacidosis in non-diabetic patients, particularly when initiated via online prescribing without rigorous monitoring, due to starvation induced by gastrointestinal side effects.

If you are taking tirzepatide (Mounjaro) for weight loss, especially through an online service, be aware that you can develop a dangerous condition called euglycaemic ketoacidosis. This means your blood becomes acidic due to ketones, even if your blood sugar stays normal. Watch for symptoms like nausea, vomiting, abdominal pain, and fatigue. If you feel unwell, check your ketones if possible and seek medical attention immediately. Do not ignore gastrointestinal side effects as they can lead to starvation and acidosis.

Tirzepatide use is associated with a probable risk of acute pancreatitis, characterized by a strong temporal correlation between drug initiation and symptom onset, and clinical resolution upon discontinuation.

If you are taking tirzepatide and develop severe, persistent upper abdominal pain, nausea, or vomiting, stop the medication immediately and seek medical attention. Do not assume the pain is just from gallstones or indigestion, especially if it started shortly after beginning the drug. Early discontinuation can prevent severe complications.

Bariatric arterial embolization (BAE) produces modest, transient weight loss (mean 7.0% at 4-5 months, 4.2% at 12 months) in patients with BMI ≥30 who have failed nonoperative management and are ineligible or unwilling to undergo metabolic-bariatric surgery.

If you have obesity (BMI ≥30) and haven't been able to lose weight through diet, exercise, or standard medications, and you are not a candidate for or do not want surgery, BAE might be an option. It involves a minimally invasive procedure to block blood flow to part of the stomach, which reduces hunger hormones. Expect modest weight loss (around 4-7%) over the first year, but it requires ongoing support from a weight management program. It is not a standalone fix and results vary significantly between individuals.

GLP-1 receptor agonists (GLP-1RAs) may indirectly improve autoimmune thyroid disease (AITD) outcomes by reducing systemic inflammation, improving insulin sensitivity, and modulating the gut-thyroid axis, rather than through direct thyroidal effects.

If you have thyroid autoimmunity and are considering GLP-1RAs for weight or diabetes, expect that your thyroid medication doses may need adjustment as you lose weight. The drug likely helps your thyroid health indirectly by lowering body-wide inflammation and improving metabolic health, rather than directly attacking thyroid antibodies. There is no strong evidence yet that it cures thyroid disease, but it is generally safe regarding thyroid cancer risk in humans. Work closely with your endocrinologist to monitor your thyroid levels during weight loss.

Women with non-diabetic obesity experience greater cardiovascular benefits from GLP-1 RAs, particularly regarding heart failure hospitalization and stroke reduction, compared to men.

Women with obesity may derive even greater heart protection from GLP-1 medications than men, especially regarding heart failure prevention. This is particularly true for postmenopausal women who are at higher risk for heart failure with preserved ejection fraction (HFpEF). Discussing your specific heart failure risk with your provider is crucial.

State-of-the-art anti-obesity medications (AOMs) like GLP-1 analogues are highly effective appetite suppressants but require continuous use, as discontinuation leads to inevitable weight regain.

Understand that obesity medications like Semaglutide or Tirzepatide are long-term treatments. Stopping them will likely lead to weight regain. Plan for continuous use as part of your long-term health strategy.

Current randomized controlled trial evidence does not demonstrate a statistically significant increase in thyroid cancer risk with the use of incretin-based therapies (GLP-1RAs and dual GIP/GLP-1RAs).

Current high-quality randomized trial data does not support a claim that GLP-1 or GIP/GLP-1 drugs cause thyroid cancer in the general population. However, the evidence is very low certainty because these trials are too short and too small to rule out a rare, long-term risk. Clinicians should continue prescribing these drugs for their proven benefits while adhering to the FDA boxed warning for patients with a specific family history of medullary thyroid cancer.

Preoperative use of GLP-1 receptor agonists is associated with reduced rates of periprosthetic joint infection (PJI) and hospital readmission in patients undergoing total hip and knee arthroplasty, particularly among those with diabetes or morbid obesity.

If you are taking a GLP-1 RA (like Ozempic or Wegovy) before hip or knee replacement surgery, current evidence suggests it may lower your risk of joint infection and hospital readmission, especially if you have diabetes or obesity. However, because these drugs cause rapid weight loss, your surgical team must carefully monitor your nutritional status (e.g., albumin levels) to ensure you are not malnourished, which could increase complication risks. Do not stop the medication without consulting your surgeon, as the net benefit appears positive in many cases, but close monitoring is essential.

Epitalon, a tetrapeptide, extends cellular lifespan by activating telomerase and lengthening telomeres, while also modulating pineal gland function to restore melatonin synthesis.

Epitalon is an investigational peptide that may extend cellular lifespan by activating telomerase and restoring melatonin production. While animal studies show promising lifespan extension, human data is limited to small studies without long-term safety validation. It is not FDA-approved for anti-aging.

BPC-157 and TB-500 enhance tissue repair and angiogenesis in aged tissues, showing promise in small pilot studies for chronic pain and wound healing.

BPC-157 and TB-500 are peptides that may help heal tissues, tendons, and muscles by promoting blood vessel growth and reducing inflammation. Small studies suggest they can relieve chronic pain and heal wounds, but they are not FDA-approved for these uses, and long-term safety is unknown.

Semax enhances neuroplasticity and cognitive function in aging by upregulating BDNF and modulating neurotransmitter systems, showing benefits in stroke recovery and cognitive decline.

Semax is a peptide that may improve brain health by increasing BDNF, a key factor in neuroplasticity. Russian studies suggest it can help stroke recovery and cognitive function, but it is not FDA-approved for these uses, and independent Western validation is lacking.

Short-term intensive insulin therapy can induce T2DM remission in newly diagnosed patients with high blood glucose levels (HbA1c ≥ 10% and FBG ≥ 11.1 mmol/L) by restoring beta-cell function.

If you were just diagnosed with Type 2 Diabetes and your blood sugar is very high, your doctor might suggest a short course of insulin. This isn't forever; it's used to quickly lower your blood sugar and give your pancreas a break so it can start working better on its own. This is most effective for people recently diagnosed.

Retatrutide, a triple-hormone receptor agonist (GLP-1/GIP/Glucagon), can cause intractable, secretory diarrhea and acute kidney injury, particularly when used off-label via unregulated online sources with unestablished dosing protocols.

If you are using retatrutide or similar GLP-1 agonists obtained from online sources, be aware that dosing is not standardized and risks are higher. Intractable diarrhea and kidney injury are serious potential side effects. Seek regulated medical care for weight loss management to ensure safe dosing and monitoring.

Higher baseline levels of Myostatin are associated with significant functional decline (Gait Speed and 6MWD) in older adults with sarcopenia, while inflammatory markers (IL-6, hsCRP) show less consistent or no correlation with functional decline.

While not yet a standard clinical test, high Myostatin levels may predict functional decline in sarcopenic older adults. In contrast, common inflammatory markers (CRP, IL-6) did not correlate with functional decline in this study, suggesting they may not be the primary drivers of functional loss in this population.

GLP-1 agonists like semaglutide may reduce the exposure (efficacy) of ALK tyrosine kinase inhibitors like alectinib due to delayed gastric emptying.

Be aware that taking semaglutide might reduce how much cancer medication your body absorbs. However, slow titration (starting low and going slow) may help mitigate this interaction.

Chronic GIPR agonism may lead to desensitization that mimics functional antagonism, potentially explaining why both agonists and antagonists result in weight loss.

There is a theoretical possibility that long-term use of GIP-activating drugs could lead to receptor desensitization, acting like a blocker. However, current clinical evidence does not strongly support this in the brain, and these drugs remain effective for weight loss. Monitor your progress with your doctor.

Unimolecular tetra-receptor agonists (TC4) simultaneously activate GLP-1R, GIPR, GcgR, and Y2R, resulting in superior metabolic efficacy (weight loss and glycemic control) compared to mono- or dual-agonists by leveraging synergistic receptor engagement.

This research describes a new class of peptide drugs that target four metabolic receptors (GLP-1, GIP, Glucagon, and PYY) simultaneously. In preclinical studies, this approach showed strong potential for treating obesity and type 2 diabetes with fewer side effects like nausea than older drugs. It is not yet available for human use.

Tirzepatide administration is associated with novel postmarketing adverse events including palpitations, musculoskeletal pain, and headaches, which were not prominent in initial clinical trials.

If you experience palpitations, muscle pain, or headaches after starting Tirzepatide, report these to your doctor. These are not the typical stomach issues and may require dose adjustment or injection site changes.

Tirzepatide, a dual GLP-1/GIP receptor agonist, may modify the natural course of lipedema by targeting its underlying immunometabolic, inflammatory, and fibrotic pathophysiology, rather than solely reducing body weight.

If you have lipedema, especially with insulin resistance, talk to your doctor about tirzepatide. It’s not just for weight loss; it may help reduce the inflammation and fibrosis causing your pain and stiffness. Since it’s a newer treatment for lipedema, ask about clinical trials or off-label use if appropriate for your case.

Heterozygous variants in the POMC gene (specifically p.Arg90His, p.Ser94Gly, p.Ser94=, and p.Ala195=) are associated with an intermediate obesity phenotype in adults, likely due to haploinsufficiency affecting melanocortin peptide processing.

If you carry a heterozygous POMC variant, you may have an intermediate form of genetic obesity that responds differently to standard interventions. This information can help tailor your treatment plan, though functional validation of specific variants is still needed.

Tirzepatide as an adjunct to insulin in adults with Type 1 Diabetes and overweight/obesity produces significant body weight reduction and reduced insulin requirements, but current evidence is insufficient to establish durable glycaemic benefit or long-term safety.

For adults with Type 1 Diabetes and obesity, Tirzepatide is a promising tool for significant weight loss and reducing insulin needs. However, it is not yet proven to reliably improve long-term blood sugar control or safety. If used, it requires careful monitoring for side effects like nausea and potential risks like DKA, especially if insulin is reduced too aggressively. It is currently an investigational option, not a standard of care.

BPC-157 accelerates tissue repair (tendons, muscles, ligaments, GI mucosa) by stimulating angiogenesis and modulating inflammation, though it lacks FDA approval and robust human clinical trials.

BPC-157 is a peptide studied for its ability to speed up the healing of tendons, muscles, and gut lining. While animal studies show promising results for tissue repair, it is not yet approved by the FDA for human use. It is sometimes used off-label in sports medicine, but robust human clinical trials are still needed to confirm its safety and efficacy.

In specific preclinical models (OVX rats, T2D mice), high-dose GLP-1 agonists can improve bone mass and microarchitecture, but these effects require doses much higher than those approved for human obesity treatment.

Animal studies show GLP-1s *can* help bones, but only at doses far higher than what humans take. This suggests the drug itself isn't a 'bone builder' at standard doses, and the bone loss seen in humans is likely due to weight loss, not a direct toxic effect of the drug.